SynAct Pharma Valuation

Is SYNACT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SYNACT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SYNACT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SYNACT's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SYNACT?

Key metric: As SYNACT is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for SYNACT. This is calculated by dividing SYNACT's market cap by their current book value.
What is SYNACT's PB Ratio?
PB Ratio	2.3x
Book	SEK 169.16m
Market Cap	SEK 385.30m

SYNACT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-5.4x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does SYNACT's PB Ratio compare to its peers?

The above table shows the PB ratio for SYNACT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	9.4x
INIT Initiator Pharma	12.4x	-40.0%	SEK 362.8m
IMMU Mendus	0.6x	92.4%	SEK 418.9m
LIPUM Lipum	7.4x	-22.2%	SEK 354.2m
CURAS Curasight	16.9x	n/a	DKK 225.4m
SYNACT SynAct Pharma	2.3x	n/a	SEK 385.3m

Price-To-Book vs Peers: SYNACT is good value based on its Price-To-Book Ratio (2.3x) compared to the peer average (9.4x).

Price to Book Ratio vs Industry

How does SYNACT's PB Ratio compare vs other companies in the SE Biotechs Industry?

8 Companies	Price / Book	Estimated Growth	Market Cap
COMBI CombiGene	0.6x	n/a	US$4.59m
EXPRS2 ExpreS2ion Biotech Holding	0.6x	-11.9%	US$3.66m
SCOL Scandion Oncology	0.5x	69.7%	US$1.52m
DIABIO Diagonal Bio	0.5x	n/a	US$1.23m

8 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: SYNACT is good value based on its Price-To-Book Ratio (2.3x) compared to the Swedish Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is SYNACT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SYNACT PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	2.3x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate SYNACT's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

AstraZeneca

UK£162.4b

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

AZN

UK£1,462.00

5.0%

8.2%

Swedish Orphan Biovitrum

SEK 99.6b

An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.

SOBI

SEK 290.00

-2.7%

14.5%

PMD Device Solutions

SEK 35.3m

A digital medical device company, develops and sells respiratory monitoring solutions in Ireland.

PMDS

SEK 1.36

-8.1%

n/a